Endocyte has had a huge run this year.

Most of that appears to be on the back of their CAR-T approach.

However, they are moving in to Phase 3 in mCRPC with radio ligand tech.

Here’s their presentation.

I think Zenith looks better from an efficacy and tolerability standpoint.

http://investor.endocyte.com/static-files/63da75b4-017f-45ed-88ce-fa336394cbda

Bfw